Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Acelyrin Inc (SLRN)

Acelyrin Inc (SLRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases GlobeNewswire - Tue May 13, 12:00PM CDT

SLRN : 2.27 (+1.79%)
ALMS : 11.31 (-1.57%)
Alumis Stockholders Approve Merger with ACELYRIN GlobeNewswire - Tue May 13, 12:00PM CDT

SLRN : 2.27 (+1.79%)
ALMS : 11.31 (-1.57%)
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis GlobeNewswire - Tue May 6, 3:30PM CDT

SLRN : 2.27 (+1.79%)
ALMS : 11.31 (-1.57%)
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis GlobeNewswire - Thu May 1, 12:30PM CDT

SLRN : 2.27 (+1.79%)
ALMS : 11.31 (-1.57%)
Alumis and ACELYRIN Announce Amended Merger Agreement GlobeNewswire - Mon Apr 21, 5:30AM CDT

SLRN : 2.27 (+1.79%)
ALMS : 11.31 (-1.57%)
Alumis and ACELYRIN Announce Amended Merger Agreement GlobeNewswire - Mon Apr 21, 5:30AM CDT

SLRN : 2.27 (+1.79%)
ALMS : 11.31 (-1.57%)
Author
3 Biopharmaceutical Stocks Bucking the Sell-Off MarketBeat - Thu Apr 10, 6:00AM CDT

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

CORT : 87.30 (-0.78%)
DBVT : 18.29 (-0.44%)
SLRN : 2.27 (+1.79%)
ABBV : 227.45 (+1.85%)
ALMS : 11.31 (-1.57%)
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger GlobeNewswire - Fri Apr 4, 3:34PM CDT

SLRN : 2.27 (+1.79%)
ALMS : 11.31 (-1.57%)
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan GlobeNewswire - Thu Mar 13, 6:00AM CDT

SLRN : 2.27 (+1.79%)
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger GlobeNewswire - Tue Mar 4, 8:01AM CST

SLRN : 2.27 (+1.79%)

Barchart Exclusives

This Dividend ETF Has Crushed the S&P 500 in 2025. Should You Buy It Before 2026? Barchart - Mon Dec 15, 6:30PM CST
After trouncing the S&P 500 this year, FDD looks best approached gradually or on pullbacks, since most of the easy upside is likely behind it and future returns will probably come from steadier dividends and slower price appreciation rather than another explosive rally. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot